A Year In Review
The TPD field is experiencing unprecedented growth, with the number of assets skyrocketing from just 21 in 2014 to 398 in 2024. Breakthroughs in PROTACs, molecular glues, and emerging degradation technologies are pushing the field forward, with novel modalities such as DUB inhibitors and protein proximity inducers gaining momentum.
Despite challenges in clinical translation, 2024 saw significant milestones, including the approval of Inavolisib for endocrine-resistant breast cancer and the first TPD therapy for Parkinson’s disease entering the clinic. As investments shift towards next-generation modalities, the industry is poised for further innovation…
Download Now
Stay ahead of the curve with the Beacon TPD 2024 Landscape Review. This report delivers exclusive insights into drug development, trial activity, investment trends, and regulatory shifts that are shaping the future of TPD. Whether you’re a biotech leader, investor, or researcher, this report is packed with the data-driven intelligence you need to make informed decisions and seize new opportunities. Download now to gain the competitive edge.
Part 1: The Drug and Trial Landscape
Part 2: The Commercial Landscape & Future of TPD
Report Contents
The Drug Landscape
Discover how TPD drug development has surged, with over 2,000 assets now tracked—88% still in preclinical stages, highlighting the field’s rapid innovation
The Trial Landscape
Explore the rise of clinical trials in TPD, with a record number of new trial initiations in 2024 and an increasing focus on combination therapies and non-oncology indications.
The Commercial Landscape
Track the latest investment and deal trends as funding shifts toward next-generation modalities, with a strong focus on protein degraders and proximity-based therapeutics.
The Future of TPD
Get an exclusive look at what’s next for TPD, from emerging targets and novel effectors to upcoming clinical milestones and data releases.
Regulatory Announcements
Review the major regulatory updates from 2024, including fast-track designations, IND approvals, and the latest TPD assets expanding into new disease areas.
You May Also Be Interested In...
TPD: 2024 Landscape Review
Strategic Insights for Biopharma Innovation Report
H1 2024 Oncolytic Viruses Landscape Review
H1 2024 Cancer Vaccine Landscape Review
The 2024 H1 TPD Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Find Out More
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape. Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts.
With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.
Any questions? Get in touch
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
